Podcasts about Moderna

Estrenamos nueva tertulia en la 9.ª temporada de 'El Faro': 'On the rocks', un encuentro con cuatro mujeres a las que no nos vamos a cansar de escuchar: Nativel Preciado, Julia Navarro, Pilar Cernuda y Amalia S. Sampedro. Y, como cada jueves, Antonio Lucas nos deja su 'Destello' y nos llevamos 'El Faro por el mundo', esta vez hasta Buenos Aires, con la corresponsal Berta Reventós, que nos ha hablado de 'Moira', la serie que arrasa en Argentina, y nos ha confirmado que los argentinos son bastante modernos.

Por fin hemos estrenado la nueva tertulia del faro, On The Rocks con Pilar Cernuda, Julia Navarro, Nativel Preciado y Amalia Sánchez Sampedro... El tema que les ha tocado ha sido Moderno, Moderna, y han estado hablando de su juventud como mujeres comparada con la de ahora

What stops a promising platform from becoming an investable company? Kevin Walton, CEO of Baseimmune, has watched this from both sides, first as an investment banker and now running a 23-person biotech through a strategic pivot he led himself.He and Nick Capman get into beachhead decisions, why most preclinical teams run their experiments in the wrong order, how to keep a distributed team aligned when the CEO is an ocean away, and what investors actually weight when science, team, execution, and strategy are all on the table.Some of what comes up:Run the experiment that could kill the program first, before the supporting package existsAccumulating incremental data feels like de-risking and mostly isn'tPick fast and cheap on a CRO and you'll pay for it twiceBuild culture from where you actually are, not from where you'd like to beWrite decisions down, name one owner, and accept that ambiguity compounds faster at distanceHire a scientific advisory board that will argue with youScience gets you the meeting. Team, strategy, and execution decide what happens afterAbout Kevin WaltonKevin Walton is CEO and a board director at Baseimmune, a London biotech developing active immunotherapies for fibrosis with IPF as its lead indication. Before Baseimmune he held corporate development and business development leadership roles at Moderna, StrideBio, Curis, and G1 Therapeutics, following a start in investment banking and consulting. He holds a law degree from Duke University School of Law.About The FDA GroupThe FDA Group helps life science organizations rapidly access the industry's best consultants, contractors, and candidates. Our resources assist in every stage of the product lifecycle, from clinical development to commercialization, with a focus on staff augmentation, auditing, remediation, QMS, and other specialized project work in Quality Assurance, Regulatory Affairs, and Clinical Operations. Learn more: https://www.thefdagroup.com/

Matigt fredagssvenskan där vi ringer Yannick Geiger som berättar förtroendet men kravbilden från Riveiro. Brännan om återkomsten i Mjällby och det där omtalade tatuerings-talet! Långt snack om mörkret i KFF och Jonte med ett GÄNG brandtal. Malmös kurva pekar sakta uppåt, men med fortsatta moln på himmelen? Dessutom (efterlängtat?) snack om boken Fotbollsagenterna.Medverkande:Christoffer Svanemar, August Spångberg, Josip Ladan, Jonatan Sjöström, Yannick Geiger & Andreas Brännström90MinSvenskan görs i samarbete med:ATG:Läs om våra senaste tankar gällande spel på: https://www.atg.se/k2618 år gäller för spel och stödlinjen.se finns om du upplever minsta problematik med spelande.Tillsammanslag Big 9: https://www.atg.se/tillsammans/lagsid...TV4 Play:TV4 Play Sport Fotboll via 90MinSvenskan! Streama Allsvenskan, Superettan och Serie A med vår dunderdeal hos TV4 där ni får 349kr/mån i 6 månader. Signa upp här: https://www.tv4play.se/kampanj/svenskanZalando:Zalando är den ULTIMATA plattformen att spetsa till sin höstgarderob med varumärken som Samsö Samsö, Björn Borg, Ralph Lauren, Adidas och OÄNDLIGT många fler. Utöver ett enormt brett sortiment så har Zalando alltid fria returer, och leveranstiden är 1-2 dagar. Klicka er in på https://www.zalando.se och kika runt!TCL:90MinSvenskan görs tillsammans med TCL - en av världens största TV-tillverkare. Vi vill tipsa om TCL Mini LED som ger dig den perfekta TV-upplevelsen när du ser Allsvenskan. Skarpare detaljer, perfekt ljus och allt som behövs för att se just ditt favoritlag.Sociala Medier:Instagram - https://www.instagram.com/90MinSvenskan/X/Twitter - https://x.com/90MinSvenskanTikTok - https://www.tiktok.com/@90MinSvenskanTidskoder:00:00 Intro07:00 Samtal med Yannick Geiger18:30 AIK27:00 Samtal med Andreas Brännström42:30 Fotbollsagenterna & spelaruppror under Brännström?56:59 Kalmar1:18:25 Malmö1:31:00 Avrundning Hosted on Acast. See acast.com/privacy for more information.

Limiting the side effects of cancer treatments has been an animating force in the field of oncology for many years, and there's been progress to report on that front, but what if you could target cancer tumors without using radiation or chemotherapy and instead generate heat from inside the tumor to kill cells? That's the quest of our guest today, Dr. Hadiyah-Nicole Green, whose promising research using lasers and nanoparticles to eliminate tumors received Breakthrough Device Designation from the FDA earlier this year. “The laser beam that we're using is low power like a laser pointer, and without activation by the laser, the nanoparticles are harmless. Both are targeted just at the site of the tumor so because we don't use systemic delivery, we avoid all of the systemic side effects,” she explains.Dr. Green is also the founder and president of the Ora Lee Smith Cancer Research Foundation, named for an aunt who raised her and who died of cancer without pursuing curative treatment because of her fear of the side effects. Shortly after, her aunt's husband also died of cancer, opting for treatments that took a heavy toll on his body. “At 22 years old, I saw the horrors of cancer and the horrors of cancer treatment and just felt in my heart that there has to be something better than this,” she tells host Michael Carrese.On this fascinating episode of Raise the Line from Elsevier, we'll explore the science behind Dr. Green's approach, the challenges of raising the millions of dollars needed for human clinical trials, and rethinking the current funding landscape for cancer treatments.Mentioned in this episode:Ora Lee Smith Cancer Research Foundation If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

Le prime pagine dei principali quotidiani nazionali commentate in rassegna stampa da Davide Giacalone. Il bollo che non si paga per auto e moto piccole, Canada e UE, Crosetto e le interferenze estere, la FED rialza i tassi, i Sudtirolesi e l'AfD. Si chiama Social Freezing, ed è la possibilità per le donne di congelare gli ovuli per rimandare nel tempo la maternità. Un tema che sta entrando sempre più nel dibattito pubblico, ma oggi è ancora una possibilità accessibile solo a chi può permettersela. Una proposta di legge punta a trasformarla in un'opportunità per tutte. Ne abbiamo parlato con Donatella Gianforma di Donna Moderna. Viaggio nell'arte a Verona, al Palazzo Maffei, con la direttrice di Palazzo Maffei, Vanessa Carlon. È ancora emergenza caro carburanti. Benzina e gasolio continuano a salire, con la benzina che ha superato i 2,12 euro al litro e il diesel arrivato ad una media di 2,30 euro. E domani scade l'attuale taglio delle accise sul gasolio: il governo avrebbe predisposto una nuova proroga di una settimana e una successiva fino al 5 ottobre ma con il dimezzamento del taglio. Noi però vogliamo capire in questo spazio, con i nostri ospiti, chi può e chi non può fare qualcosa rispetto a questi aumenti. Con noi Lorenzo Pace, giornalista del Sole 24 Ore e Gianni Murano, presidente di Unem (unione energie per la mobilità), l'associazione che rappresenta le principali imprese che operano in Italia nei settori della raffinazione, della logistica, della distribuzione di prodotti petroliferi. In diretta il ministro dei trasporti e delle infrastrutture e vicepremier Matteo Salvini. All'interno di Non Stop News, con Giusi Legrenzi, Lucrezia Bernardo, Enrico Galletti e Lorenzo Dardano.

A new mRNA vaccine for advanced melanoma is generating significant interest, but what does it actually mean for patients? In the latest episode of Life by a Thousand Cuts, A/Prof Tony Dicker examines the recent trial of Moderna's personalised mRNA vaccine, intismeran, in combination with pembrolizumab. He explains how the treatment is designed around the individual mutations in a patient's melanoma, the early evidence for improved recurrence-free survival, and some of the practical challenges involved in producing a personalised vaccine. For GPs, the key distinction is that this is not a vaccine to prevent melanoma. Rather, it is an emerging treatment approach for patients who already have advanced melanoma, and one that patients may increasingly ask about as more results receive media attention. Prefer a visual format? Watch this podcast here.   Next steps in your learning journey

Envíame un mensajeLa devoción a María Desatanudos se ha hecho enormemente popular, pero también ha recibido críticas, especialmente en algunos ambientes católicos tradicionales. Algunos argumentan que es demasiado moderna, que no procede de ninguna aparición de la Santísima Virgen y que su popularidad está estrechamente relacionada con el Papa Francisco. Pero ¿cuál es realmente su origen?En este programa investigamos la historia del famoso cuadro de María Desatanudos, pintado hacia el año 1700 y venerado en Augsburgo, Alemania. También descubriremos que la imagen de María “desatando el nudo” tiene una raíz muchísimo más antigua: San Ireneo de Lyon, en el siglo II, utilizó precisamente la imagen del nudo de la desobediencia de Eva que es desatado por la obediencia de María.Analizamos las principales objeciones contra esta devoción: ¿necesita una advocación mariana provenir de una aparición? ¿Es moderna la novena? ¿Tiene fundamento bíblico y patrístico? ¿Existe algo doctrinalmente problemático en la imagen?Y compararemos la Virgen Desatanudos con otras devociones católicas que tampoco surgieron de una aparición mariana.¿Estamos realmente ante una invención moderna o ante una representación relativamente reciente de una enseñanza mariana que se remonta a los primeros siglos del cristianismo?Support the showYouTubeFacebookTelegramInstagramTik TokTwitter

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today's episode delves into some of the latest breakthroughs, regulatory updates, and strategic maneuvers reshaping the landscape of drug development and patient care. Starting with remarkable advancements in drug approvals, Scholar Rock's Isembldy (apitegromab), a monoclonal antibody designed to inhibit myostatin, has secured FDA approval for treating spinal muscular atrophy. This approval came after successful Phase 3 trials and marks a significant milestone in managing neuromuscular diseases. By targeting the myostatin pathway, which regulates muscle growth, Isembldy offers hope for improved motor function in patients suffering from this debilitating condition. Meanwhile, Pharming's Joenja (leniolisib) received an expanded label from the FDA, now approved for pediatric patients aged four and older with activated phosphoinositide 3-kinase delta syndrome, reflecting ongoing efforts to tackle rare autoimmune disorders. Telix Pharmaceuticals has also made strides with the approval of Pixclara (floretyrosine F 18) for PET imaging of glioma, enhancing diagnostic precision for both adult and pediatric brain cancer patients. In clinical trial successes and challenges, GSK and Hansoh Pharmaceutical reported that their antibody-drug conjugate, risvutatug rezetecan, significantly reduced the risk of death in Phase 3 trials for relapsed small-cell lung cancer by 54%. This underscores the potential of targeted therapies in oncology, especially where second-line treatments have been limited. AstraZeneca's Tagrisso (osimertinib), meanwhile, continued to demonstrate its efficacy with a notable reduction in death risk in early-stage EGFR-mutated non-small cell lung cancer at an eight-year follow-up, reinforcing its value as an adjuvant therapy. However, AstraZeneca faced setbacks with camizestrant's Phase 3 trial failing to meet primary endpoints in estrogen receptor-positive breast cancer. A similar challenge arose with Enhertu (trastuzumab deruxtecan) in HER2-mutant non-small cell lung cancer, indicating ongoing difficulties in developing effective combination therapies. Turning to strategic business developments, Johnson & Johnson's decision to divest its orthopedics unit DePuy Synthes to Apollo Equity Management for $20 billion reflects a strategic refocus on core areas like pharmaceuticals and medical devices. Similarly, Novo Nordisk's rebranding as 'Novo' signals an effort to strengthen its competitive stance against Eli Lilly within the GLP-1 agonist market, crucial for managing metabolic disorders such as diabetes. In collaborations and licensing deals aimed at broadening access to healthcare innovations, Bio Usawa's partnership with Axmed is set to enhance access to affordable biologic medicines across Africa, a vital step towards expanding healthcare reach in underserved regions. In oncology research advancements, Owkin has licensed its AI-driven K Pro scientist platform to Servier to accelerate drug discovery through artificial intelligence and machine learning applications. Regulatory challenges continue to shape industry dynamics. The FDA has postponed its decision on Exelixis's Zanzalintinib combined with Roche's Tecentriq for metastatic colorectal cancer until March 2027, reflecting rigorous scrutiny to ensure safety and efficacy. Meanwhile, Cellectis has opted to halt its allogeneic CAR-T programs amid increasing competition from in vivo approaches, showcasing strategic adaptability within the rapidly evolving field of cell therapy. In recent news focusing on mRNA technology and personalized cancer vaccines, Moderna's flu vaccine approval using mRNA technology marks a pivotal moment for this platform after facing skepticism over the years. Furthermore, Moderna and Merck have reported positive Phase 3 results for their personalized mRNA-based cancer vaccine—an advancement positioning them as leaders in personalized cancer immunotherapy following success in melanoma treatment. The sector remains dynamic as companies navigate these complex environments. Breakthroughs such as ivonescimab's success provide optimism for future innovations that could significantly enhance patient care and treatment outcomes across various diseases. The emphasis on mRNA technologies and personalized medicine heralds a new era of targeted therapies poised to redefine standards of care across multiple disease areas. As these initiatives progress, they hold potential not only for improving existing treatment paradigms but also for pioneering new frontiers in healthcare delivery. As these developments unfold, they highlight the industry's dual focus on advancing scientific innovation while navigating complex regulatory landscapes and competitive pressures. The implications are profound: promising enhanced patient outcomes through novel therapies while prompting strategic realignments among key industry players. These initiatives not only aim to improve existing treatment paradigms but also pioneer new frontiers in healthcare delivery.Support the show

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. First, let's delve into the innovative work being done by Grove Biopharma. Founded in 2020 in Chicago, this company is at the forefront of developing polymer-peptide hybrids to target intracellular protein-protein interactions, areas traditionally deemed undruggable. These interactions are crucial regulatory components in numerous cellular processes and are implicated in diseases like cancer and neurodegenerative disorders. However, their smooth protein surfaces present a challenge for traditional small molecule drugs, which struggle to find suitable binding pockets. Similarly, biologics like antibodies and peptides, despite their high binding affinities, face difficulties penetrating cell membranes due to their size and instability. Grove Biopharma addresses these issues through its proprietary Bionics Biologics™ technology. Developed by Nathan Gianneschi at Northwestern University, this approach uses protein-like polymers to mimic proteins with enhanced stability and cellular penetration. These polymers, adorned with peptide branches via living polymerization, maintain peptide binding properties while overcoming previous limitations in drug delivery. This breakthrough has already shown promise in preclinical studies. A 2023 study in Science Advances revealed the efficacy of targeting membrane protein CD36 for treating macular degeneration in mice, while a 2024 study demonstrated PLPs' ability to penetrate neurons and target mitochondria in Huntington's disease models. Moreover, a 2026 Nature Communications publication introduced HYDRAC, a new PLP class capable of degrading MYC and KRAS proteins, reducing tumor growth in mice. Grove Biopharma's pipeline is robust, targeting key areas in cancer and neurodegeneration. Despite challenges typical of the biotech landscape—such as toxicity concerns during clinical trials and scalability issues—Grove's unique platform offers the flexibility needed to address multiple targets effectively. Shifting focus to industry-wide developments, recent advancements highlight significant strides in personalized medicine. Moderna and Merck's mRNA cancer vaccine has shown promising results in a phase 3 study, marking an important step forward for customized healthcare approaches based on genetic profiles. This not only offers hope for cancer treatment but also signifies a wider shift towards more tailored therapeutic strategies. Regulatory updates also play a critical role in shaping industry dynamics. The appointment of Dr. Angelo De Claro as chief of the FDA Oncology Center of Excellence is pivotal. His focus on modernizing regulatory practices aims to expedite drug approvals while ensuring that innovative treatments reach patients more swiftly. However, the FDA's decision to delay approval for Exelixis' tyrosine kinase inhibitor with Roche's Tecentriq underscores the complexities involved in novel therapies' assessments. On the geographical front, Singapore's launch of a biotech hub in Boston highlights the global nature of biotech development. This move strengthens historical ties and emphasizes international collaboration's importance in accelerating scientific research. In clinical trials, AbbVie's success with Qulipta (atogepant) for menstrual migraine prevention is noteworthy. It not only expands therapeutic options for women but also underscores a growing focus on gender-specific health issues within clinical research. Meanwhile, new RAS-targeting therapies continue to emerge as Revolution Medicines' Rasonque gains approval for advanced pancreatic cancer treatment—a significant milestone in addressing previously undruggable mutations. Industry dynamics are further illustrated by leadership changes at major firms like Takeda. The departure of long-time R&D chief Andy Plump often signals strategic shifts that could influence research priorities and corporate focus. Novartis recently faced setbacks with late-stage asset failures impacting its market position and raising investor concerns about its strategic direction concerning mergers and acquisitions. On a similar note, Takeda undergoes organizational changes amid potential strategic shifts following its CEO appointment—demonstrating volatility within companies striving for competitive advantage through effective leadership. Promising developments at the FDA include solidifying leadership with Karim Mikhail at CBER and Michael Davis at CDER—crucial appointments ensuring operational stability amidst past disruptions under former commissioner Marty Makary—and appointing Jared Seehafer as deputy commissioner focusing on AI integration into regulatory processes. Significant financial movements continue highlighting investor interest: Frazier adds over $1 billion targeting small-mid-sized biotech firms while Samsung Biologics secures manufacturing deals emphasizing strategic partnerships' importance globally. Scientific developments also reveal challenges; Silence Therapeutics maintains polycythemia vera leadership despite emerging hurdles while Novo Nordisk halts heart disease studies reflecting complexities validating interleukin-6 as therapeutic targets. AI integration gains momentum transforming operational efficiencies across various functions from R&D to human resources optimizing overall effectiveness within life sciences organizations—a trend poised to reshape people strategy profoundly impacting medical affairs evidenced evaluations enhancing decision-making processes ultimately improving patient outcomes significantly moving forward amidst this dynamic industry landscape filled with opportunities and risks requiring agility and forward-thinking strategies to capitalize on emerging scenarios efficiently and effectively ensuring continued success thriving amidst transformations occurring rapidly around us today, tomorrow, and beyond!Support the show

Rysk-japanska kriget 1904–1905 är för många i dag en relativt okänd konflikt, trots att det i sin samtid uppfattades som ett av de mest betydelsefulla krigen sedan Napoleonkrigen. Japans seger väckte enorm uppmärksamhet världen över. En asiatisk stat hade besegrat en europeisk stormakt i ett modernt storkrig och därmed rubbat föreställningar om den europeiska militärens självklara överlägsenhet.Japan hade sedan Meijirestaurationen 1868 genomgått en snabb politisk, industriell och militär modernisering. Nu visade landet vad denna omvandling hade åstadkommit både på land och till sjöss. Efter hårda strider i Manchuriet och belägringen av Port Arthur kom det avgörande sjöslaget vid Tsushima i maj 1905, där den japanska flottan i praktiken krossade den ryska 2:a Stillahavseskadern, som huvudsakligen hade sänts från Östersjön.För Ryssland blev nederlaget en svår prestigeförlust. Samtidigt skakades tsarväldet av den revolutionära oro som kulminerade under 1905 och som krigets motgångar bidrog till att förstärka.I avsnitt 49 av Militärhistoriepodden tar sig idéhistorikern Peter Bennesved och historikern Martin Hårdstedt an rysk-japanska kriget och dess betydelse för 1900-talets militära och politiska utveckling.Kriget har ofta beskrivits som en föregångare till första världskriget. Det var ett tidigt exempel på industriell krigföring i stor skala. Under belägringen av Port Arthur mötte anfallande soldater skyttegravar, taggtråd, kulsprutor och tungt artilleri – företeelser som senare skulle komma att prägla västfronten under första världskriget. Även sjökriget gav en föraning om framtidens konflikter. Moderna slagskepp spelade huvudrollen, samtidigt som torpedbåtar och sjöminor fick stor betydelse. Vapnen var inte nya, men rysk-japanska kriget visade tydligt vilken effekt de kunde få i ett modernt sjökrig.Mest känt är slaget vid Tsushima den 27–28 maj 1905. Under amiral Heihachirō Tōgō besegrade den japanska flottan den ryska eskadern genom bättre beredskap, effektiv eldgivning och skicklig manövrering. Bara ett fåtal ryska fartyg lyckades nå Vladivostok. Trots segern fick Japan också erfara att en militär triumf inte nödvändigtvis gav alla de politiska vinster som befolkningen väntade sig. I freden i Portsmouth erkändes Japans starka ställning i Korea, landet övertog ryska rättigheter kring Port Arthur och södra Manchuriska järnvägen och fick den södra delen av Sachalin. Däremot fick Japan inget krigsskadestånd, vilket utlöste omfattande protester och upplopp i Tokyo. Rysk-japanska kriget innebar därmed inte bara slutet på en konflikt utan början på en ny maktordning i Östasien. Japan hade etablerat sig som stormakt, men motsättningarna kring landets växande inflytande i Korea, Manchuriet och Kina skulle fortsätta att skärpas under de följande årtiondena. Tillsammans med Japans fortsatta expansion och de växande motsättningarna till USA bidrog denna utveckling så småningom till den konflikt som kulminerade i Stillahavskriget och anfallet mot Pearl Harbor 1941. Hosted on Acast. See acast.com/privacy for more information.

This episode digs into a controversial theory about SARS-CoV-2 origins, focusing on documents, timelines, and lab-to-lab collaboration rather than the usual public narrative. Jim Haslam lays out his case for how the virus was engineered as part of animal vaccine research, while George Howard helps connect the investigative and public-transparency angles. The conversation also focuses on UNC records, Rocky Mountain Lab, Wuhan, and the broader issue of dual-use biodefense research. Jim Haslam Author of COVID-19: Mystery Solved: It leaked from a Wuhan lab but it's not Chinese junk: https://a.co/d/gD8JQqi https://jimhaslam.substack.com/ https://x.com/jhas5 George Howard Pajama scientist and former business owner. More than 1K Younger Dryas Impact citations since 2007. Founding Partner Titan Network. https://carolinaflu.org/ https://x.com/CosmicTusk Key Topics Jim Haslam explains the core thesis of his book, COVID-19 Mystery Solved, arguing that SARS-CoV-2 emerged from a U.S. led research network rather than a simple Wuhan lab accident. The discussion centers on Ralph Baric, the University of North Carolina, and documents Haslam says show early work on a SARS-like genome and a furin cleavage site. George Howard frames the issue as a transparency battle, pointing listeners to the Carolinaflu.org petition and UNC's ongoing resistance to releasing records. The hosts revisit the mainstream lab leak narrative and debate when public opinion shifted from "impossible" to "probably lab leak." A major thread is the claim that the virus was developed as an animal vaccine model involving bats, mink, deer, ferrets, and hamsters. Haslam argues the research was dual-use and aerosol-focused, with Vincent Munster and Tony Fauci's biodefense ecosystem playing major roles in making the pathogen highly transmissible. The conversation returns to FOIA material, email trails, and what the guests describe as incriminating silences or resignations from researchers involved in the work. The group discusses the February 2020 call, the proximal origin paper, and how the scientific and media response shaped the public story. George Howard emphasizes that the UNC document fight is still unfinished, with thousands of pre-pandemic records allegedly still withheld. The episode closes with a call for listeners to support transparency efforts and read Haslam's book for the full argument. To gain access to the second half of show and our Plus feed for audio and podcast please clink the link http://www.grimericaoutlawed.ca/support. For second half of video (when applicable and audio) go to our Substack and Subscribe. https://grimericaoutlawed.substack.com/ or to our Locals  https://grimericaoutlawed.locals.com/ or Patreon https://www.patreon.com/grimericaoutlawed   https://www.skool.com/audiobooks THE GRIMOIRE Audiobook Club and Library https://pegsandjokers.ca/ Family and Friends Cards and Pegs Boardgame online https://www.simulationmaps.com/#products Disaster Maps, Volcano Sim, Asteroid Sim, Shipwreck Map, UFO Map etc Support the show directly: https://open.spotify.com/show/2punSyd9Cw76ZtvHxMKenI?si=ImKxfMHgQZ-oshl499O4dQ&nd=1&dlsi=4c25fa9c78674de3 Watch or Listen on Spotify https://grimerica.ca/support-2/ Our Adultbrain Audiobook Podcast and Website: www.adultbrain.ca Check out our next trip/conference/meetup - Contact at the Cabin www.contactatthecabin.com Join the chat / hangout with a bunch of fellow Grimericans Https://t.me.grimerica grimerica.ca/chats   Discord Chats Darren's books www.acanadianshame.ca Sign up for our newsletter http://www.grimerica.ca/news InstaGRAM https://www.instagram.com/the_grimerica_show_podcast/ Purchase swag, with partial proceeds donated to the show www.grimerica.ca/swag ART - Napolean Duheme's site http://www.lostbreadcomic.com/ MUSIC Tru Northperception, Felix's Site sirfelix.bandcamp.com   Timestamps 00:00 — Opening banter and guest introductions 01:02 — Jim Haslam begins the origin theory 02:01 — Ralph Baric, DARPA, and the alleged pre-confession 03:23 — Animal vaccine research and the Wuhan connection 05:43 — The Facebook fact-checker angle 07:14 — When the mainstream narrative changed 08:44 — Mink, ferrets, and serial passage 10:04 — The self-spreading animal vaccine theory 13:15 — Immune evasion and why it mattered 14:41 — Bats as the reservoir host 17:25 — Fauci's Rocky Mountain Lab 21:25 — Cell phone data and the Wuhan BSL-4 timeline 26:25 — The failed DARPA grant and second-round research 30:56 — Variants, especially D614G 35:45 — Vincent Munster and animal transmission models 40:57 — Carolinaflu.org and the UNC records fight 46:33 — Was the leak intentional or accidental? 50:12 — The Seattle traveler and the WA1 strain 51:44 — Aerosol spread, masks, and particle size 59:24 — The alleged withheld antidote 60:59 — The smoking gun email 64:28 — Baric's overlap with Moderna's mRNA research 69:12 — The theory of withholding the antidote 73:24 — "Not my lab" and the bat lady's three words 76:08 — The January 2020 phone calls and February conference call 79:33 — Fauci, guilt, and the turning point 82:43 — Dual-use research and regulatory failures 86:41 — Closing reflections and why the case matters                        

Emilia Pardo Bazán (A Coruña, 1851-Madrid, 1921). Es una de las grandes españolas del XIX y principios del XX. Es la autora de 'Los Pazos de Ulloa', 'La madre naturaleza', 'Insolación' o 'La tribuna' , entre otras, y de más de seiscientos cuentos. 'Un viaje de novios' se publicó en 1881. 

Fragt man Menschen, vor welcher Krankheit sie am meisten Angst haben, dann hört man sehr oft: Krebs. Gleichzeitig gibt es große Fortschritte in der Krebs-Behandlung: Müssen wir also bald Krebs nicht mehr fürchten?// Alle Quellen und weiteren Spezials findest Du hier: https://www.quarks.de/daily-quarks-spezial/ Von Christina Sartori.

Josh's Guests:  Roberto Pinelli, M.D. - author, Awakening The Pineal Gland What does this tiny organ do to protect our health? Charles Frohman - The NATIONAL HEALTH FEDERATION Local governments battle Cell Towers, how do you stay safe, What is the long term fight? Health Freedom news, ObamaCare updates Joshua Lane Roundup of the news John Campbell, PhD  on Moderna's clinical trial reporting substantially higher rates of adverse reactions among people who received its new mRNA injection than among those who received a standard Flu vaccine find us at: www.HeresToYourHealthWithJoshuaLane.com  

Turpinām izzināt, kur un kā Latvijā plūst piena upes. AS "Pampāļi" ir viens no vadošajiem un lielākajiem noslēgta cikla lauksaimniecības uzņēmumiem Latvijā, kurā viens no virzieniem ir piena ražošana. Kā darbojas moderna piensaimniecība? To dodamies noskaidrot uz Saldus novadu.  Roboti, 5G, govju uzpasēšana 24 stundas diennaktī - ne tas vien atrodams Pampāļos. Par pienu, par govīm, par barību un daudz ko citu runājam raidījumā Kā labāk dzīvot. Tiekamies ar uzņēmuma "Pampāļi" vadītāju Mārtiņu Vaļko, uzņēmuma "Pampāļi" Piena lopkopības asistente Irita Lapsenberga un uzņēmuma mārketinga vadītāju Līgu Vaļko.

Poul Thorsen, the researcher behind vaccine-autism studies cited for years to shut down debate, is now facing fraud charges. Dr. Robert Malone joins Del to break down the scandal and what it means for the public's trust in vaccine science.Then, Jefferey Jaxen follows the road to the mRNA rollout, from Fauci's NIH inner circle and Moderna's rise to new research examining lipid nanoparticles, immune disruption, and cancer progression. Plus, Sen. Ron Johnson reports on Canada's Allison Inquiry, where witnesses are sharing accounts of injuries they say followed COVID-19 vaccination.And, Del sits down in the studio with Kim Rogers, known to millions as “The Worm Queen,” to discuss parasites, cleansing, and her own health journey. Finally, COVID hero Dr. David Brownstein joins the show to discuss his upcoming Vaccine and Immunology Conference.Guests: Dr. Robert Malone, M.D., M.S., Sen. Ron Johnson, Kim Rogers, David Brownstein, M.D.Airdate: September 10, 2026Become a supporter of this podcast: https://www.spreaker.com/podcast/the-highwire-with-del-bigtree--3620606/support.

Britain, France and Canada have announced sweeping sanctions on trade with Israeli settlements in the occupied West Bank. The British Foreign Secretary accused Israeli settlers of "ethnic cleansing" against the Palestinians living there. Israel responded by ordering the closure of the British consulate in Jerusalem. The U.S. has yet to push back against the sanctions. The U.N. says settler violence has reached unprecedented levels and this summer, dozens of prominent figures in Israel signed a letter demanding action to 'eradicate Jewish terrorism' in the West Bank. Among them was former Israeli Prime Minister Ehud Olmert. He joins the program from Tel Aviv.   Also on today's show: Frank Kendall, Former US Secretary of the Air Force; Noubar Afeyan, Co-founder & Chairman, Moderna  Learn more about your ad choices. Visit podcastchoices.com/adchoices

"It's really hard to justify a test that has any complications if there isn't any reasonable expectation of benefit," says Dr. Rita Redberg, who has spent her career trying to help fellow clinicians consider the actual value of routine screenings and diagnostic testing in asymptomatic patients. Dr. Redberg -- a cardiologist and professor of medicine at the University of California, San Francisco for more than three decades -- is one of the leading voices advocating for a “high-value care” approach, an uphill fight in a healthcare system that tends to reward action over restraint. Her highest profile effort was launching the instructive “Less is More” series in JAMA Internal Medicine when she served as its editor-in-chief for 14 years. On a related track, her research on the assessment of the safety and effectiveness of medical technology, specifically high-risk cardiovascular devices, has yielded a troubling picture. "We found only 1% of devices enter the market through the FDA's most rigorous approval process. The high-quality evidence to support benefit for these devices that I had assumed was present, wasn't actually there.” Join Raise the Line host Lindsey Smith for an eye-opening exploration of what Dr. Redberg considers to be the overlooked risks and false reassurance of common tests and procedures, and her efforts to put the “do no harm” principle of medicine at the forefront of everyday practice.Mentioned in this episode:UCSF School of MedicineJAMA Internal Medicine's Less is More Series If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

Dolly Parton was more than a voice. She was a strategist, a visionary, and arguably one of the greatest creator capitalists in the history of the entertainment industry. While the world mourned her passing and celebrated her extraordinary musical catalog, the most important tribute may be the one that focuses not on her songs, but on the decision she made decades before most people had ever heard her name. Long before the creator economy had a name, Dolly Parton was already living by its highest principles. In 1967, before she had a single top ten hit as a recording artist, she founded her own publishing company with her uncle Bill Owens and began owning the copyright to everything she wrote. That single decision would go on to shape the entire trajectory of her career, her wealth, and her legacy in ways that continue to compound to this day. This is just some of the topics that Pirates Christopher Lochhead, Eddie Yoon and Bri Clark discuss on this episode of The Pirate Street Journal. Each week, the Category Pirates pick three headlines worth paying attention to and break down the category underneath. You're listening to Christopher Lochhead: Follow Your Different. We are the real dialogue podcast for people with a different mind. So get your mind in a different place, and hey ho, let's go.   Dolly Parton Said No to Elvis and Changed Everything When Elvis Presley expressed interest in recording “I Will Always Love You,” Dolly Parton was initially thrilled. That excitement faded quickly when she learned his condition. He wanted half the songwriting profits on a song he had absolutely nothing to do with creating. She said no, a decision that shocked nearly everyone around her at the time. That refusal was not reckless. It was rooted in financial security she had quietly built for herself through royalties and intellectual property ownership. Because she had already established her publishing company years earlier, she had the runway to walk away from one of the biggest stars in the world. When Whitney Houston recorded the song for “The Bodyguard” soundtrack in 1992, Dolly Parton owned one hundred percent of it and earned an estimated ten million dollars from that single cover in the 1990s alone.   Owning Your Value in a Changing Economy Dolly Parton understood something that most creators are only beginning to grasp today. The real shift happening in modern business is not simply about artificial intelligence. It is about moving away from being paid for your time as a proxy for value, and toward being paid for the actual value you create and own. Paul McCartney once said that he and John Lennon simply did not know you could own songs. Mick Jagger and Keith Richards lost their early catalog too. Dolly Parton did not make that mistake. She built an intellectual capital foundation so strong that it funded Dollywood, the Imagination Library, and a net worth estimated by Forbes at around 450 million dollars, all stemming from the simple act of owning what she created from the very beginning.   A Legacy That Reaches Far Beyond Music Dolly Parton turned down the Presidential Medal of Freedom three times. She declined once because her husband was ill, once because of Covid restrictions, and again because she did not want her acceptance to be interpreted as a political statement. In a world obsessed with personal branding and self-promotion, she consistently chose mission over recognition. Her philanthropy was as strategic as her business decisions. She helped fund Moderna’s Covid vaccine research, launched the Imagination Library which has distributed over 330 million books to children, and created an economic ecosystem through Dollywood that supports 23,000 jobs and generates 1.8 billion dollars in annual economic impact. Dolly Parton wrote Jolene and I Will Always Love You in the same evening, turned down Elvis, said yes to Whitney, and quietly became one of the most financially powerful and generous artists the world has ever seen. To hear about the topics in this week's The Pirate Street Journal, download and listen to this episode. You can also read more Pirate Street Journal entries in the Category Pirates newsletter.   We hope you enjoyed this episode of Christopher Lochhead: Follow Your Different™! Christopher loves hearing from his listeners. Feel free to email him, connect on Facebook, X, LinkedIn, and subscribe on Apple Podcast / Spotify!

Gender-bending athletes, the bizarre Mitch McConnell “frozen” footage, healthcare distrust, race, politics, surveillance, Red Lobster's Endless Shrimp, and Flock cameras all collide in this episode of Neph 2 America.David “The Raven” Corbo and TopLobsta are joined by Matthew Heppner of Straight Bible for a wide-ranging cultural commentary episode built around viral clips, political absurdity, conspiracy claims, Biblical discussion, and the kind of internet rabbit holes that only Neph 2 America can produce.The show opens with footage of Mitch McConnell appearing to remain almost motionless on the Senate floor for hours before his temporary disappearance from public view. That launches a broader conversation about American politics, Israel, dual citizenship, the illusion of political choice, and how much power voters really have over the system.From there, the crew reacts to the Gary, Indiana power outage and the debate over “environmental racism,” then moves into a heated discussion about race, representation, government, sports ownership, Jewish identity, ancient Israel, Egypt, Biblical history, the “synagogue of Satan” passage, and claims surrounding Leon Trotsky and a Judas statue.The episode then shifts into distrust of the modern healthcare system, Anthony Fauci, COVID-era policies, Moderna's cancer vaccine research, and a provocative conversation about race and the future of healthcare. The guys also break down the strange economics and internet lore surrounding Red Lobster's Endless Shrimp promotion and bankruptcy.One of the biggest clips comes when an average man disguises himself and enters a women's Division I track event, sparking a discussion about biological sex, transgender athletes, women's sports, and competitive fairness.Later, “Messages from Mom” returns before the crew dives into Flock license-plate cameras, Home Depot, Walmart, Costco, surveillance culture, police access, privacy, and the possibility of manufactured fear or political psyops.The episode closes with a viral claim involving PepsiCo, flavor research, and aborted fetal cell lines.Which story was the craziest to you: frozen Mitch, the D1 track race, Endless Shrimp, or Flock cameras? Drop your take in the comments.► Subscribe for more Biblical analysis, Christian worldview discussions, and conspiracy research through a Biblical lens.Listen on Spotify, Apple Podcasts, and everywhere podcasts are available.00:00 Intro05:39 Mitch McConnell Vanishes?07:10 Frozen for Hours on the Senate Floor08:34 Israel, Politics & the Illusion of Choice14:31 Blue Blockers & John Pounders17:16 Dual Citizenship in American Politics21:15 Gary Indiana Blackout & Environmental Racism29:31 Dual Citizenship Debate Continues32:17 Race, Government & Representation35:21 UFC Ownership & Jewish Athletes38:26 Ancient Israel, Egypt & Biblical History41:16 The “Synagogue of Satan” Discussion45:54 Leon Trotsky & the Judas Statue Claim47:14 Healthcare Distrust & Moderna Cancer Vaccine55:35 The Future of Healthcare & Race57:36 Red Lobster's Endless Shrimp Returns68:48 Man Enters Women's D1 Track Race80:43 Messages From Mom87:08 Flock Cameras, Home Depot & Surveillance91:10 PepsiCo & Fetal Cell Research ClaimBecome a supporter of this podcast: https://www.spreaker.com/podcast/nephilim-death-squad--6389018/support.☠️ Nephilim Death Squad — New episodes 5x/week.Join our Patreon for early access, bonus shows & the private Telegram hive.Subscribe on YouTube & Rumble, follow @NephilimDSquad on X/Instagram, grab merch at toplobsta.com. Questions/bookings: chroniclesnds@gmail.com — Stay dangerous.

Grandes de la rumba y el guaguancó registrados por la discografia independiente cubana de los años 50. Celeste Mendoza apoyada por la etiqueta Gema de los hermanos Alvarez Guedes; el grupo "Guaguancó Matancero" con Saldiguera y Virula en la delantera vocal y Papín y sus rumberos con Fuico, su cantante estrella, desde el catálogo Puchito de Jesús Gorís. Sonidos que nos recuerdan que, afortunadamente, no existieron barreras sociales entre músicos populares y productores discográficos. Carlos Embale todo lo cantó bien. Sonero inmenso brilló además en la rumba y el guaguancó. Presencia de la obra del maestro Ernesto Lecuona en las voces más destacadas del canto lirico cubano del siglo XX. Sarita Escarpenter, María de los Ángeles Santana unen sus voces para cantar "Tus ojos azules" y por separado: "Al fin" y "Mariposa". Esther Borja con el pianista Nelson Camacho nos recuerda la faceta del genio de Guanabacoa como musicalizador. "La rosa del jardinero" es un texto de los poetas españoles Serafín y Joaquín Álvarez Quintero. Los tesoros de la música popular cubana, todos los domingos, los reservamos aquí para ti. Tres piezas del pianista, arreglista y compositor Moisés Simons en voz de la Rita Montaner correspondientes al despegue discografico de la intérprete como artista exclusiva de la etiqueta norteamericana Columbia. En agosto de 1928, durante uno de sus viajes a Nueva York, grabó con el apoyo de los pianistas Rafaelito Betancourt y Nilo Menéndez: "Rumba guajira" y "Palmira". Un año más tarde, en julio de 1929, la feliz coincidencia de Rita y Bola de nieve al piano iluminó el mundo del disco con esta versión del pregón: "Con picante y sin picante". El ayer y hoy de una isla y su música. Harold López Nussa y CimaFunk en este formidable tributo al timonel del tren vanvanero Juan Formell. Del "Buey cansao" a una mirada más contemporánea del clásico de Samuell: "Los ojos de Pepa" nos sigue acompañando este notable pianista. Continuamos con unos tracks del álbum "Black and white" del año 1989. El trabajo discografico del trompetista Jorge Varona que, lamentablemente, resultó ser póstumo nos devuelve el sonido de este formidable instrumentista. Desde formaciones como el Conjunto Casino, la banda de Beny Moré, la Orquesta de Música Moderna e Irakere, Varona completó su paso memorable por los escenarios. En la despedida un recuerdo para el gran Emiliano Salvador a la manera del saxofonista, arreglista y compositor Carlos Averhoff (junior). Cubakústica, todas las semanas compartimos contigo más de cien años de música popular cubana

Kelli Hoffman, co-executive director of the Noblesville nonprofit Healthy & Dwell, joins Larry Lannan to discuss what adults with serious mental illness face when they leave treatment and have nowhere stable to live. Healthy & Dwell operates a supportive housing home in Noblesville where residents pay 30% of their income toward rent and utilities and receive life-skills coaching and help navigating benefits — a model Hoffman says has kept residents employed, connected and out of acute care for three years. The organization is privately funded and is now building duplexes to expand. Larry opens with commentary on why housing insecurity and mental illness are easy to overlook in a prosperous county, and why a discharge plan is not the same thing as a safe place to sleep. Also in this episode: the first successful late-stage trial of a personalized mRNA cancer vaccine from Merck and Moderna, and a South Carolina man with more than 2,000 pairs of socks chasing a Guinness World Record. Learn more: healthyanddwell.org More local news: larryinfishers.com Sponsored by Citizens State Bank — mycsbin.com/larry. Member FDIC. Equal Housing Lender.

In this episode of the Limitless Podcast, Dr. Matthew Preston and Dr. Thaon Simms welcome back Ryan Strachan for a wide-ranging conversation on investing, Jamaica's energy future, infrastructure, the Jamaica Stock Exchange, and the forces that could reshape the Jamaican economy.⚡ A major focus is the future of JPS and Jamaica's electricity sector. Ryan explores what the upcoming changes could mean for renewable energy, battery storage, electricity prices, manufacturing, household expenses, and economic growth. Could cheaper energy unlock an entirely new phase for Jamaican businesses and investors?

A new mRNA vaccine for melanoma is making headlines. Moderna and Merck recently announced results from their clinical trial suggesting that this new vaccine, in combination with the cancer drug Keytruda, reduced recurrence rates in patients. The companies have not yet released full data from the trial. So, how does the vaccine work? And does this mark the beginning of a new era of cancer treatments using mRNA vaccine technology? Ira talks with physician Michael Postow, whose patients were part of the drug trial at Memorial Sloan Kettering Cancer Center. Guest: Dr. Michael Postow is chief of the melanoma service at Memorial Sloan Kettering Cancer Center. Transcript will be available after the show airs on sciencefriday.com. Subscribe to this podcast. Follow our show on Instagram, TikTok, Facebook, and Bluesky @scifri and sign up for our newsletters. Got a science question that's keeping you up at night? Call us: 877-472-4374 Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

For millions of young women and girls, often the first place they turn with questions about their bodies isn't a doctor's office, it's social media which can lead to encountering many misconceptions and outright misinformation. Or, if the right voices show up, it can mean something else entirely. Our guest today, Dr. Charis Chambers, is one of those voices. She's a board-certified OB/GYN with specialty certification in Pediatric & Adolescent Gynecology, and Chief Medical Officer at Clue, a leading period and cycle-tracking app. She's also the founder of The Period Doctor, a platform she launched in 2019 to provide medically accurate reproductive health information and to place more minority physicians in the spaces where patients are already looking for answers. As she tells Raise the Line from Elsevier host Lindsey Smith, Dr. Chambers embraces the role of being a bridge between generations: "I can serve as a medical mediator where I advocate for the child and then educate the parent so that the child's concerns are met." Stay tuned to this important conversation to also learn about: Her new book, The Period and Puberty Parenting Revolution, which tackles many of the same myths she encounters every day in her clinic; Why stubborn myths around periods rarely hold up once you ask where they come from; How she thinks about the responsibility, and limits, of being a trusted medical voice on social media. Mentioned in this episode: Clue The Period Doctor The Period and Puberty Parenting Revolution If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

Michael Frazis is back to unpack a market moving faster than ever. From cracks appearing in the AI infrastructure trade and a potential software comeback, to personalised cancer vaccines and the evolution of his own investing strategy, Michael explains why he's moved from simply holding great growth companies to systematically taking profits and managing momentum. Plus, we dig into Nvidia's biggest long-term threat, why Apple may have played the AI boom perfectly, and the thinking behind Frazis Capital Partners' new ROAR Active ETF.In this episode:00:00 Why markets could be entering a more volatile era02:27 The AI trade, leverage & the Ashenbrenner blow-up08:11 Is the AI infrastructure boom starting to crack?12:25 Cheaper AI models, China & why Apple may be the winner16:50 The software comeback & where Michael sees opportunities22:17 Michael Frazis' new rules for growth & momentum investing39:25 GLP-1s, Moderna & the next wave of biotech breakthroughs46:49 Why Frazis Capital launched the ROAR Active ETFStocks & ETFs Mentioned: Frazis Capital Partners ROAR Active ETF (ASX: ROAR), Nvidia (NASDAQ: NVDA), Broadcom (NASDAQ: AVGO), Apple (NASDAQ: AAPL), Alphabet (NASDAQ: GOOGL), Meta Platforms (NASDAQ: META), Amazon (NASDAQ: AMZN), Microsoft (NASDAQ: MSFT), Taiwan Semiconductor Manufacturing Company (NYSE: TSM), Alibaba Group (NYSE: BABA), Atlassian (NASDAQ: TEAM), WiseTech Global (ASX: WTC), Xero (ASX: XRO), REA Group (ASX: REA), Datadog (NASDAQ: DDOG), Tesla (NASDAQ: TSLA), AMD (NASDAQ: AMD), Palantir Technologies (NASDAQ: PLTR), Wesfarmers (ASX: WES), Commonwealth Bank (ASX: CBA), Eli Lilly (NYSE: LLY), Novo Nordisk (NYSE: NVO), Moderna (NASDAQ: MRNA), Tempus AI (NASDAQ: TEM), Clarity Pharmaceuticals (ASX: CU6)Check out Lioncrest's new ETF ROAR here: https://lioncrestpartners.com/#roar-etf———Want to get involved in the podcast? Record a voice note or send us a messageAnd come and join the conversation in the Equity Mates Facebook Discussion Group.———Want more Equity Mates? Across books, podcasts, video and email, however you want to learn about investing – we've got you covered.Keep up with the news moving markets with our daily newsletter and podcast (Apple | Spotify)We're particularly excited to share our latest show: Basis PointsListen to the podcast (Apple | Spotify)Watch on YouTubeRead the monthly email———Looking for some of our favourite research tools?Download our free Basics of ETF handbookOr our free 4-step stock checklistFind company information on TIKRResearch reports from Good ResearchTrack your portfolio with Sharesight———This podcast is intended for education and entertainment purposes only. Any advice is general advice and has not taken into account your personal financial circumstances. Before acting on general advice, you should consider if it is relevant to your needs. If unsure, speak to a financial professional. The host of this podcast and their guests may have positions in the companies mentioned. Equity Mates Media is part of the Betashares Group but maintains editorial independence and operates under Australian Financial Services licence 540697. Hosted on Acast. See acast.com/privacy for more information.

a16z General Partner Jorge Conde sits down with Moderna CEO Stéphane Bancel to discuss a major milestone for mRNA technology: positive Phase 3 results from Moderna and Merck's individualized treatment for melanoma, after more than a decade of work on personalized cancer vaccines. Stéphane explains how the treatment works by sequencing an individual patient's tumor and healthy cells, identifying the mutations most relevant to their cancer, and encoding up to 34 of them into an mRNA designed specifically for that patient. Rather than simply unleashing the immune system, the goal is to teach it exactly what to recognize and attack. They also unpack the engineering challenge of manufacturing a different medicine for every patient, how Moderna has brought the process down to roughly 42 days from biopsy to treatment, and what it would take to manufacture personalized medicines at scale. Finally, Stéphane looks beyond melanoma to lung, kidney, bladder, pancreatic, and gastric cancers, as well as Moderna's longer-term work applying mRNA to rare genetic and autoimmune diseases. Resources: Follow Stéphane Bancel on LinkedIn: https://www.linkedin.com/in/st%C3%A9phane-bancel-8185251/ Follow Jorge Conde on X: https://x.com/JorgeCondeBio Stay Updated:Find a16z on YouTube: YouTubeFind a16z on XFind a16z on LinkedInListen to the a16z Show on SpotifyListen to the a16z Show on Apple PodcastsFollow our host: https://twitter.com/eriktorenberg Please note that the content here is for informational purposes only; should NOT be taken as legal, business, tax, or investment advice or be used to evaluate any investment or security; and is not directed at any investors or potential investors in any a16z fund. a16z and its affiliates may maintain investments in the companies discussed. For more details please see a16z.com/disclosures. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

a16z General Partner Jorge Conde sits down with Moderna CEO Stéphane Bancel to discuss a major milestone for mRNA technology: positive Phase 3 results from Moderna and Merck's individualized treatment for melanoma, after more than a decade of work on personalized cancer vaccines. Stéphane explains how the treatment works by sequencing an individual patient's tumor and healthy cells, identifying the mutations most relevant to their cancer, and encoding up to 34 of them into an mRNA designed specifically for that patient. Rather than simply unleashing the immune system, the goal is to teach it exactly what to recognize and attack. They also unpack the engineering challenge of manufacturing a different medicine for every patient, how Moderna has brought the process down to roughly 42 days from biopsy to treatment, and what it would take to manufacture personalized medicines at scale. Finally, Stéphane looks beyond melanoma to lung, kidney, bladder, pancreatic, and gastric cancers, as well as Moderna's longer-term work applying mRNA to rare genetic and autoimmune diseases. Resources: Follow Stéphane Bancel on LinkedIn: https://www.linkedin.com/in/st%C3%A9phane-bancel-8185251/ Follow Jorge Conde on X: https://x.com/JorgeCondeBio Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

A new personalised vaccine given in combination with a drug has stopped skin cancer returning in patients during a trial, representing a potentially watershed moment in cancer treatment. Scientists used mRNA technology, which was used for some Covid-19 vaccines.But that technology - and vaccines more generally - have become increasingly controversial in the United States since the Covid-19 pandemic. The Health Secretary Robert F Kennedy Jr, is a vaccine sceptic. In August 2025 cancelled $500m (£376m) in funding for mRNA vaccine research. The move impacted 22 projects being led by major pharmaceutical companies, including Pfizer and Moderna, for vaccines against bird flu and other viruses, according to Kennedy's department. We speak to Tom Whipple, host of the BBC's Inside Science programme, about the science of this new vaccine. And we ask how funding cuts for vaccine research could impact health outcomes not just for Americans, but for the world.For more episodes, just search 'The Global Story' wherever you get your BBC Podcasts.

On this wek's episode of WSJ's Take On the Week, host Miriam Gottfried and guest host Aaron Back, editor of WSJ's Heard on the Street, preview the upcoming employment and inflation releases in advance of the Federal Open Market Committee's September policy meeting. They analyze why these economic indicators will draw heightened focus under Federal Reserve Chairman Kevin Warsh. Then Miriam and Aaron dig into Nvidia's recent blowout earnings and whether we will see that echo in Broadcom's earnings this week. Next, Dan Rasmussen, founder and portfolio manager at Verdad Advisers, offers insight into the past year's small-cap stock surge following an extended period of underperformance relative to mega-caps. Rasmussen explains why private equity firms face a massive exit logjam from acquisitions of small companies due to inflated valuations. Finally, we ask Rasmussen: does value investing still work? This is WSJ's Take On the Week where co-hosts Telis Demos, writer for WSJ's Heard on the Street, and Miriam Gottfried, WSJ's investing and wealth management reporter, cut through the noise and dive into markets, the economy and finance—the big trades, key players and business news ahead. Have an idea for a future guest or episode? How can we better help you take on the week? We'd love to hear from you. Email the show at takeontheweek@wsj.com. To watch the video version of this episode, visit our WSJ Podcasts YouTube channel or the video page of WSJ.com Further Reading Inflation Was 3.4% in July, Down Slightly From the Previous Month Fed's Preferred Inflation Gauge Remains Above Target Range Nvidia Reports Blowout Quarter, Says Demand for AI Chips Is Getting Even Hotter Nvidia's $279 Billion Supply-Chain Gamble Nvidia Has Become a Banker to the AI Boom, Putting It on Dangerous Ground Private-Equity Firms Are Sitting on a Nine-Year Backlog A Better Mousetrap for Buying Small Stocks Moderna Shares More Than Double on Success of mRNA Cancer Vaccine For more coverage of the markets and your investments, head to WSJ.com, WSJ's Heard on The Street Column, and WSJ's Live Markets blog. Sign up for the WSJ's free Markets A.M. newsletter. Follow Miriam Gottfried here and Telis Demos here. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

For years, Moderna was a one-hit wonder, a company that bet everything on mRNA, struck gold with a COVID vaccine and then watched its stock crater as the pandemic faded. Now, the company may have found a way to fight skin cancer. An experimental mRNA-based vaccine succeeded in preventing melanoma from returning in high-risk patients, sending drug industry stocks soaring. WSJ's Xavier Martinez traces Moderna's wild ride from scrappy startup to the frontier of can treatment. Ryan Knutson hosts. Further Listening: - The FDA Commissioner on Vaccines and Public Trust - The Creator of the Record-Setting Covid Vaccine Sign up for WSJ's free What's News newsletter. Learn more about your ad choices. Visit megaphone.fm/adchoices

Send Zorba a message!Zorba's thoughts on the groundbreaking mRNA therapeutic vaccine to combat melanoma.Support the showProduction, edit, and music by Karl ChristensonSend your question to Dr. Zorba (he loves to help!):Phone: 608-492-9292 (call anytime)Email: askdoctorzorba@gmail.comWeb: www.doctorzorba.orgStay well!

P.M. Edition for Aug. 26. Tech reporter Meghan Bobrowsky tells us why the Meta settlement could change how teenagers use some of the world's most popular apps. Plus, the FDA approves a milestone therapy for pancreatic cancer. WSJ reporter Xavier Martinez discusses how the nearly $40,000-a-month drug from Revolution Medicines could change patient outcomes of one the deadliest cancers. And the FBI shuts down a sprawling hacking network linked to China that targeted NASA, the Federal Reserve and critical infrastructure. Sabrina Siddiqui hosts. Sign up for the WSJ's free What's News newsletter. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

────────────────────────────────────────[00:02:09]Dolly Parton Used to Push Vaccines — Her Health Issues Began Shortly After She Got the ShotShe was charming and they used her; she is as much a victim as anything; health issues began shortly after the Moderna shot; her husband died a year ago.────────────────────────────────────────[00:27:19]Bessent Doubled Treasury Buybacks — Soros' Right-Hand Man Running Monetary Policy While MAGA Looks AwayMAGA goes several levels down to find a Soros connection, but the direct one at the top — Scott Bessent — gets a pass because Trump chose him.────────────────────────────────────────[00:29:00]AI Is Now 41% of the S&P 500 — Worse Than Dot Com, Worse Than 1929, Worse Than BIS SaidAt the dot com high it was 26.5%; now 41%; household equities at 42% of financial assets vs 38% at the dot com peak; never seen a market this inflated.────────────────────────────────────────[00:33:28]CDC Scientist Paul Thorntson Pleading Guilty — Used Grant Money to Buy a House, Two Cars, and a MotorcycleHis fake MMR/autism study was cited to deny more than 5,000 families' vaccine injury claims; the real crime is that the fraudulent research became official policy.────────────────────────────────────────[00:39:14]Thimerosal Is Mercury — Barbaric, Dark Ages ScienceKnight couldn't wear soft contacts because of thimerosal — turned his eyes blood red; they inject that into infants with undeveloped immune systems.────────────────────────────────────────[00:47:38]Navy Mandating mRNA Flu Shots While Inviting Back Marines It Fired for Refusing the COVID ShotOf 3,748 eligible Marines contacted, only 53 returned; Navy now mandating new shots; Hegseth's reinstatement PR says nothing about what comes next.────────────────────────────────────────[00:55:57]IDF Destroying Christian Villages in Lebanon — Calling Them Hezbollah Fortresses to Justify DemolitionTroops vandalized a Christian church inside; Katz said some villages must disappear; white phosphorus deployed; collective punishment that defines Nazism.────────────────────────────────────────[01:15:46]JFK Refused to Give Israel Nuclear Technology — Source: Every One of 10,000 Unreleased Documents Points at IsraelCongress passed a law twice demanding release; Trump didn't comply; Kennedy was actively trying to stop Israel from acquiring nuclear technology.────────────────────────────────────────[01:17:16]Rabbi Shmuley Makes Violent Threats Against Tucker Carlson and Candace Owens — Calls for Jews to Be Feared, Not LovedKnight: you can't handle a debate so you threaten; the man demanding Israel be feared is outraged anyone criticizes what is done to Gaza.────────────────────────────────────────[01:53:18]The AI Bubble Has Less Than a Year — Data Centers Will Become Pickleball CourtsSteve Keen called the 2008 crash; CAPEX is 87% short of what's needed; NVIDIA becoming its own bank; when credit disappears, data centers with 3-year GPUs become worthless. ──────────────────────────────────────── Money should have intrinsic value AND transactional privacy: Go to https://davidknight.gold/ for great deals on physical gold/silver For 10% off Gerald Celente's prescient Trends Journal, go to https://trendsjournal.com/ and enter the code “KNIGHT” For high quality made in America products go to HomeSteadProducts.shop and use promo code “Knight” for 10% off your purchases Find out more about the show and where you can watch it at TheDavidKnightShow.com If you would like to support the show and our family please consider subscribing monthly here: SubscribeStar https://www.subscribestar.com/the-david-knight-show Or you can send a donation throughMail: David Knight POB 994 Kodak, TN 37764Zelle: @DavidKnightShow@protonmail.comCash App at: $davidknightshowBTC to: bc1qkuec29hkuye4xse9unh7nptvu3y9qmv24vanh7Become a supporter of this podcast: https://www.spreaker.com/podcast/the-david-knight-show--2653468/support.

Anthony Fauci is once again facing questions over the legacy of the COVID era as his lawyers launch a public legal defense fund to help cover mounting costs. We look at the continuing fallout from the pandemic, from Novak Djokovic defending his refusal to take the COVID vaccine to Moderna's latest vaccine breakthrough and renewed questions about health, personal choice and the institutions we were told to trust. I'm joined by Nathan Apffel, a Christian filmmaker and entrepreneur with more than 15 years in TV and film production, and the creator and director of The Religion Business, a documentary series investigating money, power and financial transparency within churches and religious institutions. I'm also joined by Eddie Mansfield, Managing Director of Path of Grace, a faith-based residential recovery program that has helped hundreds of women overcome drug and alcohol addiction. Drawing on his own journey through addiction and nearly two decades of sobriety, Eddie now helps women rebuild their lives through long-term recovery, community and Christ-centered teaching.   Learn more about Path of Grace: https://www.pathofgrace.net Connect with Nathan: Insta: https://www.instagram.com/religionbusiness/ Insta: https://www.instagram.com/nathan_apffel/ TikTok: https://www.tiktok.com/@nathanapffel YouTube: https://www.youtube.com/@thereligionbusiness   To get a free audio copy of my book 'How to Become a Christian in 7 Days', you can download it at https://www.russellbrand.com/how-to-become-a-christian-audiobook/ Order my new book 'How to Become Christian in 7 Days' at https://bit.ly/russellbook2 Listen to Jake's new album - https://bit.ly/JakeSmithAlbum If you want to support the show and take care of yourself properly—without turning your bathroom into a laboratory—go to tryreborn.com. It's the Reborn store: supplements, skincare, daily essentials… simple, effective, and made for people who are trying to stay strong while the world does whatever this is. Go check out tryreborn.com and grab what you need  

────────────────────────────────────────[00:02:09]Dolly Parton Used to Push Vaccines — Her Health Issues Began Shortly After She Got the ShotShe was charming and they used her; she is as much a victim as anything; health issues began shortly after the Moderna shot; her husband died a year ago.────────────────────────────────────────[00:27:19]Bessent Doubled Treasury Buybacks — Soros' Right-Hand Man Running Monetary Policy While MAGA Looks AwayMAGA goes several levels down to find a Soros connection, but the direct one at the top — Scott Bessent — gets a pass because Trump chose him.────────────────────────────────────────[00:29:00]AI Is Now 41% of the S&P 500 — Worse Than Dot Com, Worse Than 1929, Worse Than BIS SaidAt the dot com high it was 26.5%; now 41%; household equities at 42% of financial assets vs 38% at the dot com peak; never seen a market this inflated.────────────────────────────────────────[00:33:28]CDC Scientist Paul Thorntson Pleading Guilty — Used Grant Money to Buy a House, Two Cars, and a MotorcycleHis fake MMR/autism study was cited to deny more than 5,000 families' vaccine injury claims; the real crime is that the fraudulent research became official policy.────────────────────────────────────────[00:39:14]Thimerosal Is Mercury — Barbaric, Dark Ages ScienceKnight couldn't wear soft contacts because of thimerosal — turned his eyes blood red; they inject that into infants with undeveloped immune systems.────────────────────────────────────────[00:47:38]Navy Mandating mRNA Flu Shots While Inviting Back Marines It Fired for Refusing the COVID ShotOf 3,748 eligible Marines contacted, only 53 returned; Navy now mandating new shots; Hegseth's reinstatement PR says nothing about what comes next.────────────────────────────────────────[00:55:57]IDF Destroying Christian Villages in Lebanon — Calling Them Hezbollah Fortresses to Justify DemolitionTroops vandalized a Christian church inside; Katz said some villages must disappear; white phosphorus deployed; collective punishment that defines Nazism.────────────────────────────────────────[01:15:46]JFK Refused to Give Israel Nuclear Technology — Source: Every One of 10,000 Unreleased Documents Points at IsraelCongress passed a law twice demanding release; Trump didn't comply; Kennedy was actively trying to stop Israel from acquiring nuclear technology.────────────────────────────────────────[01:17:16]Rabbi Shmuley Makes Violent Threats Against Tucker Carlson and Candace Owens — Calls for Jews to Be Feared, Not LovedKnight: you can't handle a debate so you threaten; the man demanding Israel be feared is outraged anyone criticizes what is done to Gaza.────────────────────────────────────────[01:53:18]The AI Bubble Has Less Than a Year — Data Centers Will Become Pickleball CourtsSteve Keen called the 2008 crash; CAPEX is 87% short of what's needed; NVIDIA becoming its own bank; when credit disappears, data centers with 3-year GPUs become worthless. ──────────────────────────────────────── Money should have intrinsic value AND transactional privacy: Go to https://davidknight.gold/ for great deals on physical gold/silver For 10% off Gerald Celente's prescient Trends Journal, go to https://trendsjournal.com/ and enter the code “KNIGHT” For high quality made in America products go to HomeSteadProducts.shop and use promo code “Knight” for 10% off your purchases Find out more about the show and where you can watch it at TheDavidKnightShow.com If you would like to support the show and our family please consider subscribing monthly here: SubscribeStar https://www.subscribestar.com/the-david-knight-show Or you can send a donation throughMail: David Knight POB 994 Kodak, TN 37764Zelle: @DavidKnightShow@protonmail.comCash App at: $davidknightshowBTC to: bc1qkuec29hkuye4xse9unh7nptvu3y9qmv24vanh7Become a supporter of this podcast: https://www.spreaker.com/podcast/the-real-david-knight-show--5282736/support.

In this episode of The Brainstorm, Sam, Nick, and Brett break down Merck and Moderna's positive Phase 3 results for a personalized mRNA cancer vaccine, a treatment custom-built from each patient's own tumor that cut mortality from advanced melanoma by roughly 50% versus the standard of care. The team digs into cost, manufacturing scale, and why the capital poured into mRNA during COVID may be paying off in oncology. Then Brett reports back from a weekend with Grok Bot, which recovered $75 of his wife's forgotten escrow money on its first task, and the team debates why multiplayer agents could be the real threat to Microsoft's enterprise moat.Key Points From This Episode:How a custom mRNA vaccine trains the immune system against a patient's own tumor, and what Phase 3 melanoma results could mean for other cancersWhy $200K–$300K per treatment limits early use, and what we believe has to change for personalized oncology to scaleWhy agents that live inside team chat, not one-on-one, may be the real disruption to Microsoft and SlackIf you know ARK, you know we focus on long-term innovation. But that doesn't mean we ignore breaking news. Every day, we debate the latest developments in tech and markets. Now, we're bringing those conversations to you in “The Brainstorm,” a co-production from ARK, WOLF, and Public. Tune in weekly for our quick takes on what's shaping innovation right now.Learn more about WOLF: https://wolf.financialLearn more about Public: https://public.com/Disclosure: http://arkinv.st/39rzF94

What do they say about insanity? Moderna throws a ticker tape parade for its new mRNA flu shot, but the side effects and deaths already connected to it should result in the FDA immediately rescinding its approval. Why DID the FDA approve it? The US and Canada are in a trade war as the Trump administration revokes 200,000 visas from foreigners who were hoping to stay a little longer. The DOJ busts a child trafficking ring out of Ohio but the news networks stay quiet. Why?    

P.M. Edition for Aug. 24. Treasury Secretary Scott Bessent says the U.S. will go after countries and companies that do business with Iran. White House economic policy reporter Brian Schwartz says it's unclear what will happen with Iran's top trading partner: China. Plus, President Trump escalates the trade conflict with Canada, threatening 50% tariffs on autos. And Heard on the Street columnist David Wainer discusses the challenges Moderna faces in fulfilling investor hopes for a sweeping new era for cancer treatment. Pierre Bienaimé hosts. The AI Therapist: A WSJ Podcast Series  Sign up for the WSJ's free What's News newsletter. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Informed Dissent with Dr. Jeff Barke – I examine mRNA vaccines, focusing on Moderna's new flu shot, informed consent, safety concerns, adverse events, package insert warnings, vaccine mandates, and manufacturer liability while questioning whether current testing and regulatory protections adequately address the risks patients may face before making medical decisions...

What does mayhem in the bond market have to do with AI? And why are discount retailers getting a boost? Plus, how did Moderna help lift healthcare stocks? Host Imani Moise discusses the biggest stock moves of the week and the news that drove them. Sign up for the WSJ's free Markets A.M. newsletter. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Jordi Visser is a veteran macro investor with 30+ years of experience and the author of the VisserLabs Substack. In this conversation, we break down bitcoin's explosive weekly surge and why this "sigma move" signals a real bull market. We also discuss the collision of AI and crypto, why bitcoin is the purest AI trade, Stripe and Ramp's battle to control AI model routers, and how to think about sizing bitcoin in your portfolio.=======================Arch Public is an agentic trading platform that automates investment strategies across Stocks, Commodities, ETFs and Crypto. Whether you're rotating into AI & Gold, allocating to the S&P 500, or accumulating Bitcoin, Arch Public executes your plan 24/7 without ever taking custody of your assets or funds. Sign up today at https://www.archpublic.com, and start your FREE automated trading strategy! =======================Figure's $160k Community Appreciation (https://www.figure.com/crypto-community-appreciation/T&Cs (https://www.figure.com/crypto-community-appreciation/disclosures/) Need liquidity without selling your crypto? Take out a Figure Crypto-Backed Loan, allowing you to borrow against your BTC, ETH, or SOL with 12-month terms, 8.91% interest rates, and no prepayment penalties. Or check out Democratized Prime (https://figuremarkets.co/pomp) and earn ~8.5% APY on real world assets. Unlock your crypto's potential today at Figure! https://figuremarkets.co/pomp Figure Lending LLC dba Figure (NMLS 1717824). Loans subject to approval. Crypto collateral may be liquidated. Terms apply - see full disclosures at http://figure.com/disclosures/=======================For a limited time, our listeners get 50% off FOR LIFE, Free Shipping, AND 3 Free Gifts at Mars Men at https://www.Mengotomars.com.=======================0:00 - Intro1:02 - Bitcoin's weekly surge & the "sigma week" behind it5:38 - The bitcoin vibe shift & intersection with AI 15:26 - Is multiple compression a warning sign for the market?19:03 - How much bitcoin should be in your portfolio?23:27 - Moderna, AI & the future of biotech29:20 - Stripe's OpenRouter deal & the fight for AI model routers34:13 - Are model routers a threat to Anthropic and OpenAI?44:00 - Why people fear data centers more than nuclear plants54:46 - Jordi's bitcoin call to arms 

The UK issues an informational pamphlet asking nicely if migrants would please stop raping people; Moderna stock spikes on announcement of a massive medical breakthrough, and we discuss what's right with American medicine; and Elon Musk calls for Derek Chauvin's release. Ep. 2490 - - - Today's Sponsors: Boll & Branch - Sleep cooler this summer with Boll & Branch. Get 15% off your first order + free shipping at https://BollAndBranch.com/ben with code ben. PragerU - PragerU has no paywall. No smirking newscasters, no bias dressed up as "objectivity." Just the facts presented in an age appropriate, wholesome, all-American way. Go to https://PragerU.com/dailywire Golden Crest Metals - Right now GoldenCrest metals will send you a free investor kit, a free portfolio review, and up to $25,000 in free silver on qualifying purchases. Text BEN to METALS—that's 638257—go to https://GoldenCrestMetals.com/Ben, or call (888) 429-3999 - - - DailyWire: Become a Daily Wire Member and watch all of our content ad-free: https://www.dailywire.com/subscribe

Drugmakers Merck and Moderna unveil a study claiming an experimental mRNA vaccine reduced recurrence of melanoma. Progressive Democrats surprise analysts with primary wins in Florida. And a former Ukrainian defense minister says Volodymyr Zelenskyy should face a wartime election. Learn more about your ad choices. Visit podcastchoices.com/adchoices

Israel's military has confirmed for the first time that its troops opened fire on a car carrying Hind Rajab, the five-year old Palestinian child who was killed alongside six of her relatives in Gaza in 2024. The IDF is opening a criminal investigation into the deaths, as well as those of two paramedics sent to rescue her. A separate inquiry will examine the killing of fifteen emergency and aid workers in Rafah last year. Also: after six years in the US state of California, Prince Harry and his family are moving back to the UK, but will not be undertaking royal duties. At least five people have been killed by Russian missile attacks on Kyiv in the early hours of Thursday morning. The US pharmaceutical giants, Moderna and Merck, say trials of an experimental treatment for melanoma have shown signs of success. US public debt has soared to a record 40 trillion dollars. A former Meta employee, turned whistleblower, tells a court in California that Meta CEO, Mark Zuckerberg, put growth in Facebook and Instagram before child safety. We have a special report about the gold rush in Kenya that's causing security and safety concerns. Scientists say giant whales are taking advantage of the ice disappearing from East Greenland, and shares in the Chinese robot maker, Unitree, soar as it launches its new humanoid robots.The Global News Podcast brings you the breaking news you need to hear, as it happens. Listen for the latest headlines and current affairs from around the world. Politics, economics, climate, business, technology, health – we cover it all with expert analysis and insight. Get the news that matters, delivered twice a day on weekdays and daily at weekends, plus special bonus episodes reacting to urgent breaking stories. Follow or subscribe now and never miss a moment. Get in touch: globalpodcast@bbc.co.ukPhoto: Five-year-old Hind Rajab who was killed in Gaza, January 29th 2004, by the Israel Defense Forces (IDF) during the Gaza war. Credit: Family

Target reported solid earnings this morning, which is a great sign for the consumer, but the big news today was from Moderna. The company's clinical trial results for a cancer vaccine were so encouraging it was fast tracked through the trial and, while there are questions, this could change how we look at cancer in the future. We discuss why the stock is up over 100%. Plus, we end the show with the latest from OpenAI and Anthropic. Travis Hoium, Lou Whiteman, and Rachel Warren discuss: - Target Earnings- Is Target Stock a Buy?- Moderna's HUGE News- Scaling Qs- Is AI Growth Slowing?- Speed Running to an IPO Companies discussed: Target (TGT), Moderna (MRNA), Merck (MRK). Host: Travis HoiumGuests: Lou Whiteman, Rachel WarrenEngineer: Kristi Waterworth Advertisements are sponsored content and provided for informational purposes only. The Motley Fool and its affiliates (collectively, “TMF”) do not endorse, recommend, or verify the accuracy or completeness of the statements made within advertisements. TMF is not involved in the offer, sale, or solicitation of any securities advertised herein and makes no representations regarding the suitability, or risks associated with any investment opportunity presented. Investors should conduct their own due diligence and consult with legal, tax, and financial advisors before making any investment decisions. TMF assumes no responsibility for any losses or damages arising from this advertisement. We're committed to transparency: All personal opinions in advertisements from Fools are their own. The product advertised in this episode was loaned to TMF and was returned after a test period or the product advertised in this episode was purchased by TMF. Advertiser has paid for the sponsorship of this episode. Learn more about your ad choices. Visit ⁠⁠⁠⁠⁠⁠megaphone.fm/adchoices⁠ Learn more about your ad choices. Visit megaphone.fm/adchoices

#915: Moderna shares soar after a breakthrough trial of an mRNA cancer vaccine. Amazon plans to expand its drone delivery service to 500 US cities. The meal-kit delivery company Blue Apron is in shambles after a key supplier goes out of business. It's Neal's Numbers on thieves stealing $200m worth of goods from trains, millennials are actually feeling good about their future, and why answering job inquiries quickly can help you get hired. Finally, Liquid Death launches an ad that suggests using pee to cool down data centers.  Learn more at https://www.rubrik.com/mb Grab tickets to our Performance Revue show! https://www.morningbrew.com/events/brew-performance-revue-2026?utm_campaign=performance_revue_2026&utm_source=mbd Subscribe to Morning Brew Daily for more of the news you need to start your day. Share the show with a friend, and leave us a review on your favorite podcast app. Listen to Morning Brew Daily Here:⁠ ⁠⁠https://www.swap.fm/l/mbd-note⁠⁠⁠ Learn more about your ad choices. Visit megaphone.fm/adchoices

22 People are arrested in Dearborn Michigan during an anti-Islam protest, President Trump weighs in on Flock cameras, and Moderna shares double after announcing a major breakthrough in combatting skin cancer. Get the facts first with Evening Wire. - - - Ep. 3047 - - - Today's Sponsor: Lean - Get 20% off when you enter code WIRE at https://TakeLean.com  - - - Wake up with new Morning Wire merch: https://bit.ly/4lIubt3   - - - Privacy Policy: ⁠https://www.dailywire.com/privacy⁠ morning wire,morning wire podcast,the morning wire podcast,Georgia Howe,John Bickley,daily wire podcast,podcast,news podcast Learn more about your ad choices. Visit podcastchoices.com/adchoices

P.M. Edition for Aug. 19. Today the total U.S. debt passed $40 trillion. WSJ economics reporter Matt Grossman discusses what that means for how the government functions. Plus, a successful trial of a mRNA vaccine for melanoma could mean potential new treatments for a deadly cancer–and news of the trial results more than doubled Moderna's stock price. And the Federal Trade Commission says retailers have to let shoppers know when they're using their personal data to raise prices. Dave Michaels, who covers corporate law enforcement for the Journal, explains how personalized pricing works, and how the FTC is looking to rein it in. Alex Ossola hosts. How Governments in the U.S. and Europe Are Stalling the AI Buildout Sign up for the WSJ's free What's News newsletter. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.